SCHEMBL3014666

SCHEMBL3014666

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Br)ccc4OC)CC3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GAA P10253 2/20 0.38
ALOX15 P16050 1/20 0.37
DRD2 P14416 3/20 0.37
DRD4 P21917 3/20 0.37
DRD3 P35462 3/20 0.37
MAPT P10636 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 1/20 0.36
TSHR P16473 1/20 0.36
LMNA P02545 1/20 0.36
PPARG P37231 1/20 0.36
GFER P55789 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017874 0.93 LMNA (0.36) ALDH1A1HPGDHSD17B10RAB9ASMN1; SMN2
SCHEMBL3015773 0.93 GAA (0.38) ALDH1A1HPGDHSD17B10RAB9ASMN1; SMN2
SCHEMBL3019945 0.93 GAA (0.39) ALDH1A1RAB9ASMN1; SMN2GAAALOX15
SCHEMBL3010620 0.93 GAA (0.38) ALDH1A1HPGDHSD17B10RAB9ASMN1; SMN2
SCHEMBL2997817 0.93 ALDH1A1 (0.47) ALDH1A1HPGDHSD17B10RAB9ASMN1; SMN2
SCHEMBL15671681 0.92 MAPT (0.38) ALDH1A1SMN1; SMN2GAAALOX15DRD2
SCHEMBL3007655 0.92 DRD2 (0.45) ALDH1A1GAAALOX15DRD2DRD4
SCHEMBL3013312 0.92 GAA (0.39) ALDH1A1RAB9ASMN1; SMN2GAAALOX15
SCHEMBL3011490 0.92 SMN1; SMN2 (0.37) ALDH1A1HPGDHSD17B10RAB9ASMN1; SMN2
SCHEMBL3015950 0.91 DRD2 (0.39) ALDH1A1HPGDHSD17B10SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885HPGD 2894/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.